Recursion Pharmaceuticals
RXRX
2.45
-0.27
-9.93%
Recursion Pharmaceuticals
US · RXRX
#2649 by market cap
Listed 2021
2.45
-0.27
-9.93%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:59
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions decreased by 10 in the most recent period (2026/Q3).
- Total institutional ownership fell 10.1 percentage points.
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Institutional ownership
- Held by institutions
- 62.75% -10.09pp
- Institutions
- 382 -10
- As of
- 2026/Q3 vs. prior period
Holder types
Mutual Fund49.20%
Public Company4.46%
VC/PE Fund3.95%
Individual/Insider2.55%
Hedge Fund2.52%
Sovereign Wealth Fund1.10%
Private Company0.93%
Insurance Company0.27%
Family Office/Trust0.48%
Government Pension Fund0.26%
Other34.77%
Top holders as of 2026-09-30
BlackRock
8.58% · 53.48M sh
ARK Investment Management LLC
7.18% · 44.75M sh
Vanguard Portfolio Management, LLC
5.74% · 35.81M sh
State Street Global Advisors
4.81% · 30.00M sh
Vanguard Capital Management, LLC
3.69% · 23.00M sh
Baillie Gifford
2.92% · 18.17M sh
Geode Capital Management, LLC
2.23% · 13.91M sh
SoftBank Group Corp.
2.19% · 13.64M sh
DCVC
2.18% · 13.62M sh
FMR
1.83% · 11.44M sh
UBS Asset Management
1.62% · 9.71M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 10 buys · 40 sells
| Name | Role | Stake |
|---|---|---|
| Blake Borgeson | Independent Director | 0.96% |
| Christopher Gibson | Co-Founder, Former Chairman & Interim Executive Advisor | 0.86% |
| Dean Li | Director | 0.52% |
| David Hallett | Chief Scientific Officer | 0.07% |
| Ben Taylor | CFO & President of Recursion UK | 0.05% |
| Najat Khan | Chief Executive Officer | 0.03% |
| Zavain Dar | Independent Director | 0.03% |
| Franziska Michor | Independent Director | 0.02% |
| Robert Hershberg | Independent Director | 0.01% |
| Elaine Sun | Independent Director | 0.00% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-11-02 | Blake Borgeson | Independent Director | Open Market Disposition | -40,000 | $3.88 |
| 2026-11-01 | Fred Hassan | Chair of the Board | Other Acquisition | +156,658 | -- |
| 2026-10-05 | Robert Hershberg | Independent Director | Derivative Exercise and Sale | -25,000 | $2.22–5.00 |
| 2026-10-05 | Blake Borgeson | Independent Director | Automatic Disposition | -50,000 | $4.84 |
| 2026-09-30 | Dean Li | Director | Other Acquisition | +3,378 | -- |
| 2026-09-30 | Zavain Dar | Independent Director | Other Acquisition | +4,607 | -- |
| 2026-09-14 | Ben Taylor | CFO & President of Recursion UK | Sale to Issuer | -5,396 | $3.41 |
| 2026-09-07 | Najat Khan | Chief Executive Officer | Automatic Disposition | -22,408 | $3.52 |
| 2026-08-31 | Blake Borgeson | Independent Director | Automatic Disposition | -30,000 | $3.34 |
| 2026-08-20 | Christopher Gibson | Co-Founder, Former Chairman & Interim Executive Advisor | Intent to Sell (Form 144) | -77,290 | $3.39 |
| 2026-08-19 | Christopher Gibson | Co-Founder, Former Chairman & Interim Executive Advisor | Intent to Sell (Form 144) | -75,000 | $3.40 |
| 2026-08-18 | Christopher Gibson | Co-Founder, Former Chairman & Interim Executive Advisor | Intent to Sell (Form 144) | -100,000 | $3.28 |
| 2026-08-17 | Christopher Gibson | Co-Founder, Former Chairman & Interim Executive Advisor | Intent to Sell (Form 144) | -26,806 | $3.00 |
| 2026-08-16 | Ben Taylor | CFO & President of Recursion UK | Sale to Issuer | -25,018 | $3.16 |
| 2026-08-16 | David Hallett | Chief Scientific Officer | Sale to Issuer | -26,657 | $3.16 |
| 2026-08-16 | Najat Khan | Chief Executive Officer | Sale to Issuer | -80,498 | $3.16 |
| 2026-08-12 | Christopher Gibson | Co-Founder, Former Chairman & Interim Executive Advisor | Intent to Sell (Form 144) | -100,000 | $3.31 |
| 2026-08-11 | Christopher Gibson | Co-Founder, Former Chairman & Interim Executive Advisor | Intent to Sell (Form 144) | -50,000 | $3.37 |
| 2026-08-09 | Christopher Gibson | Co-Founder, Former Chairman & Interim Executive Advisor | Intent to Sell (Form 144) | -100,000 | $3.27 |
| 2026-08-06 | Christopher Gibson | Co-Founder, Former Chairman & Interim Executive Advisor | Intent to Sell (Form 144) | -100,000 | $3.25 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-11-20 19:59:48 · For reference only, not investment advice and not tailored to your situation.
Recursion Pharmaceuticals discussion 0 comments